Off-label use of Zyprexa to treat disruptive children or address pain was aired in an Anchorage courtroom last week. A previously undisclosed 2003 memo from John C. Lechleiter, who will become CEO in April, said “to seize the opportunity to expand our work with Zyprexa” by using the door it had opened with pediatricians about another medication. The company says it was only trying to respond to physician interest. Alaska is suing Eli Lilly to recoup Medicaid costs for treating undisclosed side effects such as weight gain leading to metabolic syndrome.
Consider This
by Phyllis Vine
MIWatch.org on Facebook
Relevant Sites
- Visit the Illinois neurology department of Northshore
Featured Videos
Most Popular
MIWatch Archives
This site complies with the HONcode standard for trustworthy health information:
verify here.
